Introduction
============

Tamoxifen efficacy may be influenced by a number of factors, including *CYP2D6*genotype, co-administration of drugs that inhibit CYP2D6, and adherence to tamoxifen therapy. CYP2D6 plays a major role in catalyzing the conversion of tamoxifen to its active metabolite endoxifen. Studies of the relevance of *CYP2D6*genotyping have had conflicting results due to various limitations: differences in *CYP2D6*allele coverage, phenotype classification and other confounding variables.

Methods
=======

Using archival samples from two UK cohorts of tamoxifen-treated women with invasive breast cancer (Dundee, n = 391; Manchester, n = 227), we estimated the association of inferred CYP2D6 metabolic phenotypes with recurrence-free survival time (RFS) using Cox proportional hazard models, adjusted for nodal status and tumor size. Comprehensive *CYP2D6*genotyping was performed using the AmpliChip CYP450 test.

Results
=======

Sixty percent of patients had at least one reduced-function *CYP2D6*allele and 6% had no functional alleles. Analysis of the entire group revealed a nonsignificant trend for worse RFS in patients with any reduced function alleles - HR = 1.52 (CI = 0.98 to 2.36, *P*= 0.06). In the subset of postmenopausal women on tamoxifen monotherapy, the HR for recurrence for patients with reduced functional alleles was 1.96 (CI = 1.05 to 3.66, *P*= 0.036). When the analysis was limited to four common allelic variants of *CYP2D6*\[[@B1]\], this difference was not apparent.

Conclusions
===========

This study indicates that patients with two fully functional *CYP2D6*alleles are more likely to experience the full therapeutic benefit of tamoxifen. The apparent adverse effect of reduced function alleles is best detected by a genotyping test with comprehensive *CYP2D6*allele coverage that captures uncommon variants with decreased function.
